Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable E3 SUMO-protein ligase RNF212 (RNF212) is an enzyme required for the regulation of crossing-over during meiosis, where it functions as a SUMO E3 ligase by stabilizing key meiotic recombination factors such as MSH4, MSH5, and TEX11[2][3]. RNF212 localizes to recombination sites, mediates the sumoylation of proteins involved in meiotic chromosome synapsis, and acts as a limiting factor for crossover designation, thus ensuring accurate genetic exchange and diversity[1][2][3]. Polymorphisms in RNF212 are associated with male infertility (Spermatogenic failure 62) and influence naturally occurring variation in recombination rates in humans[2][3]. This protein operates in concert with related factors such as HEI10 and RNF212B, with regulatory roles that are critical for pairing and exchange of genetic material between homologous chromosomes during gamete formation[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable E3 SUMO-protein ligase RNF212 (RNF212).